Printed from Voxsanity (voxsanity.com.au) — NCT06764485 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
You must have been diagnosed with a specific type of prostate cancer (adenocarcinoma) confirmed by a tissue or cell sample, without certain aggressive features (small cell or neuroendocrine).
You must have prostate cancer that has spread to other parts of the body, shown by bone lesions on a bone scan or tumors seen on a CT or MRI scan.
You must have no pain or only mild pain from prostate cancer, with a pain score below 4 on a standard pain questionnaire.
You must have previously been treated with one of the following hormone-blocking medications: abiraterone, enzalutamide, apalutamide, or darolutamide.
Who may not be able to join:
You may not be eligible if you have a heart condition or significant heart disease that affects how well your heart works.
You may not be eligible if the cancer has spread to your brain.
You may not be eligible if the cancer has spread to your liver.
You may not be eligible if a bone scan shows an extremely widespread pattern of cancer spread throughout the skeleton (sometimes called a "superscan") (confirm with trial site).
There may be additional eligibility requirements not listed here that the trial team will check (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Royal Adelaide Hospital, Adelaide, South Australia
+61870742336
Lyell McEwin Hospital, Elizabeth Vale, South Australia
08 7117 7265
ICON Cancer Centre - Kurralta Park, Kurralta Park, South Australia
+61884740220
Icon Cancer Centre Hobart, Hobart, Tasmania
+61 3 6240 2600
Austin Health, Heidelberg, Victoria
+613 9496 5000
Cabrini Hospital - Malvern, Malvern, Victoria
+61 3 9508 1222
Peter MacCallum Cancer Centre, Melbourne, Victoria
+61385595000
The Alfred Hospital, Melbourne, Victoria
+61390763129
St. John of God Murdoch Hospital, Murdoch, Western Australia
+61863230011
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06764485
Sponsor: Celgene
Phase: Phase 3
Status: Recruiting
Condition: Spinal Muscular Atrophy
Trial contact: 855-907-3286
More information: https://clinicaltrials.gov/study/NCT06764485
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
You must have been diagnosed with a specific type of prostate cancer (adenocarcinoma) confirmed by a tissue or cell sample, without certain aggressive features (small cell or neuroendocrine).
You must have prostate cancer that has spread to other parts of the body, shown by bone lesions on a bone scan or tumors seen on a CT or MRI scan.
You must have no pain or only mild pain from prostate cancer, with a pain score below 4 on a standard pain questionnaire.
You must have previously been treated with one of the following hormone-blocking medications: abiraterone, enzalutamide, apalutamide, or darolutamide.
Who may not be able to join:
You may not be eligible if you have a heart condition or significant heart disease that affects how well your heart works.
You may not be eligible if the cancer has spread to your brain.
You may not be eligible if the cancer has spread to your liver.
You may not be eligible if a bone scan shows an extremely widespread pattern of cancer spread throughout the skeleton (sometimes called a "superscan") (confirm with trial site).
There may be additional eligibility requirements not listed here that the trial team will check (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Celgene
Registry
ClinicalTrials.gov
Start date
13 March 2025
Est. completion
12 September 2027
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇷 Brazil
🇨🇦 Canada
🇨🇱 Chile
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇮🇳 India
🇮🇪 Ireland
🇮🇹 Italy
🇯🇵 Japan
🇵🇱 Poland
Puerto Rico
🇷🇴 Romania
🇸🇰 Slovakia
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇹🇼 Taiwan
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
16 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Radiographic progression-free survival (rPFS) by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteria
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.